DRMA
Dermata Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.07M
P/E Ratio
—
EPS
$-4.17
Beta
0.67
52W High
$8.00
52W Low
$1.10
50-Day MA
$1.28
200-Day MA
$2.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dermata Therapeutics Inc
Dermata Therapeutics Inc. is a clinical-stage biotechnology firm focused on developing pioneering treatments for dermatological conditions. The company’s leading candidate, DMT310, utilizes a proprietary delivery system aimed at improving the efficacy of therapies for acne and other skin disorders, addressing significant unmet needs in the dermatology sector. With a strategically developed pipeline and innovative technologies, Dermata is committed to enhancing skin health and improving patient outcomes. As it advances through clinical trials, the company is positioned to establish itself as a key player in the dermatology market, potentially transforming the treatment landscape for skin-related ailments.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.86M |
| Operating Margin | 0.00% |
| Return on Equity | -103.60% |
| Return on Assets | -52.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.59 |
| Price-to-Book | 0.80 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.02M |
| Float | $3.17M |
| % Insiders | 24.82% |
| % Institutions | 7.37% |
Historical Volatility
HV 10-Day
50.70%
HV 20-Day
53.87%
HV 30-Day
54.46%
HV 60-Day
77.43%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($4.00 target)
1
Strong BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026